Nicotine dependence is one of the world's leading causes of preventable death. To discover genetic variants that influence risk for nicotine dependence, we targeted over three hundred candidate genes and analyzed 3,713 single nucleotide polymorphisms (SNPs) in 1,050 cases and 879 controls. The Fagerström test for nicotine dependence (FTND) was used to assess dependence, where cases were required to have an FTND of 4 or more. The control criterion was strict: control subjects must have smoked at least 100 cigarettes in their lifetimes and had an ). This SNP exhibited evidence of a recessive mode of inheritance, resulting in individuals having a two-fold increase in risk of developing nicotine dependence once exposed to cigarette smoking. Other genes among the top signals were KCNJ6 and GABRA4. This study represents one of the most powerful and extensive studies of nicotine dependence to date, and has found novel risk loci which require confirmation by replication studies.
Introduction
The World Health Organization estimates that if current trends continue the annual number of deaths from tobacco-related diseases will double from 5 million in the year 2000 to 10 million in 2020 (1, 2) . Nicotine, a naturally occurring alkaloid found in tobacco, mimics acetylcholine, and nicotine's ability to bind to nicotinic cholinergic receptors (nAChRs) underlies the molecular basis of nicotine dependence (susceptibility to tobacco addiction, [MIM 188890] ). Chronic nicotine exposure produces long-lasting behavioral and physiological changes that include increased synaptic strength, altered gene expression, and nAChR up-regulation (3).
Although nAChRs are expressed throughout the central nervous system, the addictive effects of nicotine are thought to be mediated through mesocorticolimbic dopamine (DA) pathways (4) . It is believed that the interplay among glutamate, dopamine, and gamma-aminobutyric acid (GABA) systems is critical for the reinforcing effects of nicotine (3, 5) . Cigarettes are the predominant form of tobacco used worldwide (6) , and genetic factors are important to the etiology of nicotine dependence, with estimates of the heritability ranging from 44% to 60% (7) .
Efforts to identify susceptibility loci influencing cigarette smoking behavior through association studies have used a candidate gene approach with both case-control and family-based designs. Several candidate genes that may influence smoking have been studied, including nicotinic receptors (8) (9) (10) , nicotine metabolizing genes (11) (12) (13) , dopamine system receptors (14) (15) (16) (17) , GABA receptors (18) , and other neurotransmitters and receptors (19) (20) (21) ). There appears to be very little concordance among linkage findings and association findings in candidate genes (see Li (22) for a overview). The only genome-wide association study (GWAS) to date is by Bierut et al. (manuscript in preparation, submitted to Human Molecular Genetics simultaneously with this manuscript), which was conducted in parallel with our study and used the same casecontrol sample.
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Results
Our list of candidate genes initially numbered 448, and was divided into categories "A" and "B". All category 55 "A" genes were targeted for SNP genotyping, but because it was beyond our resources to target all of the remaining 393 category "B" genes, these were prioritized for SNP genotyping according to the results of the pooled genotyping in the parallel GWAS (Bierut et al., manuscript in preparation). Table 1 shows a summary of the results of the pooled genotyping in the candidate genes. Out of the 393 category "B" genes considered for SNP selection, 296 were targeted for individual genotyping in our candidate gene study. These were chosen using the lowest corrected minimum p-values, as defined in equation (1) Our top FDR-controlled findings were dominated by nicotinic receptor genes. Our positive association findings for the α5 and β3 nicotinic receptor subunits are novel. To date most human genetic and biological studies of the nicotinic receptors and nicotine dependence have focused on the α4 and β2 subunits since they co-occur in high-affinity receptors and are widely expressed in the brain (26) . However, mouse studies have demonstrated that of the α4β2 containing receptors that mediate dopamine release, a substantial proportion contain α5 as well (27) . This is consistent with our evidence for an important role of α5 in nicotine dependence susceptibility. Furthermore, in a brain α4β2 receptor, an α5 or β3 subunit can take the fifth position in the pentamer corresponding to β1 of muscle. Although neither α5 nor β3 is thought to participate in forming binding sites, they are able to affect channel properties and influence agonist potency because they participate in the conformational changes associated with activation and desensitization (26) . family of genes. GIRK provides a common link between numerous neurotransmitter receptors and the regulation of synaptic transmission (33). GABA is the major inhibitory neurotransmitter in the mammalian central nervous system, and is critical for the reinforcing effects of nicotine (3, 5) . We found significant evidence that the risk due to genotype is much stronger in men than in women (table 5) , where the male odds ratio was 2.2 (95% CI 1.4-3.3).
Previously reported findings in other nicotinic receptors were not among our most significant findings. In prior studies of CHRNA4, nominal association with nicotine dependence measures was reported for the SNPs rs2236196 and rs3787137 in African-American families and rs2273504 and rs1044396 in European Americans, but only rs2236196 in African-Americans remained after multiple testing correction (9) . Also in CHRNA4, rs1044396 and rs1044397 were associated with both FTND score and qualitative nicotine dependence in a family-based sample of Asian male smokers (8) . In our sample of European descent, we tested 11 SNPs for CHRNA4 including the above mentioned SNPs except rs2273504, which did not pass our stringent quality control standards. The lowest primary p-value across all 11 SNPs was 0.026 for rs2236196
(study-wide rank = 132); this particular result may be considered a single test given the specific prior finding for this SNP, and thus provides modest evidence for replication. The remaining four previously reported SNPs that we analyzed showed p-values greater than 0.8. Contrasts in these results are possibly due in part to the different ethnicities of the respective samples.
A recent study of smoking initiation and severity of nicotine dependence in Israeli women (10) analyzed 39 SNPs in 11 nicotinic receptor subunit genes. Their single SNP analyses also did not detect association to SNPs in α4, including rs2236196, rs1044396 and rs1044397, while finding nominal significance in the α7, α9, β2 and β3 subunits. Their study did not include the same SNPs in the β3 subunit and α5-α3-β4 cluster comprising our four strongest associations in nicotinic receptor genes; they did analyze our fifth ranking nicotinic receptor SNP, rs1051730, and found a suggestive p-value of 0.08 when comparing "high" nicotine dependent subjects to "low" nicotine dependent subjects, in a much smaller sample than ours.
Our study was unable to corroborate reported association findings of Beuten and colleagues (18) for the β2 subunit of the GABA B receptor GABBR2 (a.k.a. GABABR2, GABAB2
and GPR51). We genotyped 32 SNPs in GABBR2 including five SNPs reported by Beuten and colleagues (18) , three of which were the most significant in European Americans by at least one test in that study. The primary p-value in our study was greater than 0.07 for all 32 SNPs, and greater than 0.3 for the five previously reported SNPs.
Similarly, we do not find evidence for nominal association in our primary test of the 31
SNPs we genotyped for the DDC gene, which includes a SNP previously reported significant in European-Americans (34). And of the 11 SNPs covering the gene BDNF, three (rs6265, rs2030324, rs7934165) were previously reported as associated in European-American males (21); these three were not significant in our sample (primary p = 0.86, 0.088 and 0.12 respectively), and the lowest primary p-value among the remaining 8 SNPs was 0.02, which does not survive correction for the six LD bins covering the gene. Note that our primary test uses a log-additive model, while previous reports sometimes found their strongest results under other models (e.g. recessive, dominant); however, for these previously reported associations our tests for departure from the log-additive model did not find evidence for improvement under alternative modes of inheritance.
Our primary association analysis was a two degree of freedom test of the significance of adding genotype and genotype by gender interaction terms to the base predictors sex and site.
This approach helps to ensure we detect associations that are significantly influenced by gender.
The disadvantage is that the extra degree of freedom makes associations with insignificant gender interaction appear to be less significant overall.
Because our controls were highly selected, and could even be considered "protected" against susceptibility to nicotine dependence, interpretation of our results must consider the possibility that an association signal from our study may actually represent protective rather than risk effects. We used the allele more frequent in cases for reporting these data as a convention to facilitate comparison of the odds ratios among SNPs; this should not be viewed as a conclusion of how a particular variant influences the risk for nicotine dependence. The precise determination of the mechanism by which a variant alters risk can only come from functional studies.
We performed additional tests for association using only the individuals from the United States sample to determine if our primary conclusions still hold in this subset of 797 cases and 813 controls (the Australian sample alone is too small to test for association, with only 253 cases and 66 controls). We used the same logistic regression method as for the entire sample except for the omission of the term "site". The Spearman rank-order correlation of the p-values between the two tests for association was 0.87. (table S3) , which includes the genes CHRNA5 and CHRNB3, the top genes from our initial analysis. Hence, while there were some changes in the order of the results, the primary conclusion of association with the nicotinic receptors CHRNB3
and CHRNA5 remains valid when the analysis is performed on the United States subsample.
As a companion to the candidate gene study, a genome wide association study (GWAS) . This convergence from two different study designs provides further support that the signals in this gene are not random effects.
In conclusion, we have identified several genetic variants as being associated with nicotine dependence in candidate genes, the majority of which are nicotinic receptor genes. One of the SNPs implicated has a number of biologically relevant consequences, making it a particularly plausible candidate for influencing smoking behavior. These variants should be considered potential sources of genetic risk. Additional research is required to establish replication and possibly their role in the pharmacogenetics of response to nicotine dosing as well as to treatments for nicotine dependence.
Materials and Methods

Subjects
All subjects (table 6) were selected from two ongoing studies. The Collaborative Genetic
Study of Nicotine Dependence (U.S.) recruited subjects from three urban areas in the United
States and the Nicotine Addiction Genetics (Australian) study collected subjects of European ancestry from Australia. Both studies used community-based recruitment and equivalent assessments were performed. Subjects that were identified as being smokers, using the criteria that they had smoked 100 or more cigarettes in their lifetimes, were queried in more detail using the FTND questionnaire. The U.S. samples were enrolled at sites in St. Louis, Detroit, and
Case subjects were required to score 4 or more on the Fagerström Test for Nicotine Dependence (FTND) (35) during the heaviest period of cigarette smoking (the largest possible score is 10). This is a common criterion for defining nicotine dependence. Control subjects must have smoked 100 or more cigarettes in their lifetimes, yet never exhibited symptoms of nicotine dependence: they were smokers that scored 0 on the FTND during the heaviest period of smoking. By selecting controls that had a significant history of smoking, the genetic effects that are specific to nicotine dependence can be examined. Additional data from the Australian twin panels supports this designation of a control status (see Bierut et al, manuscript in preparation, submitted to Human Molecular Genetics simultaneously with this manuscript). In the U.S. study, using the sample of 15,086 subjects which were determined to be smokers (smoked 100 or more cigarettes lifetime) during the screening process, the prevalence of "nicotine dependence"
(FTND was greater than or equal to 4) was 46.4%, and the prevalence of "smoking without nicotine dependence" (FTND = 0) was 20.1%.
Candidate Gene Selection
The criteria for the selection of the candidate genes were based on known biology, correlations between nicotine dependence and other phenotypes, and previous reports on the genetics of nicotine dependence and related traits. Genes were nominated by an expert committee of investigators from the NIDA Genetics Consortium (http://zork.wustl.edu/nida) with expertise in the study of nicotine and other substance dependence. These included classic genes that respond to nicotine, such as the nicotinic receptors, and other genes involved in the addictive process.
In all, 448 genes were considered for SNP genotyping. The genes were divided into 2
categories: "A" and "B". Category "A" genes, which included the nicotinic and dopaminergic receptors, were considered to have a higher prior probability of association, and were guaranteed to be targeted for genotyping. Since our study design allowed for individual genotyping of approximately 4,000 single nucleotide polymorphisms (SNPs), the category "B" genes were too numerous to receive adequate SNP coverage once the "A" genes had been sufficiently covered.
We therefore prioritized the category "B" genes using the results of the pooled genotyping from the companion GWAS study (Bierut et al., manuscript in preparation). Genes exhibiting the most evidence for association with nicotine dependence were prioritized for coverage. Some genes are larger than others and therefore may receive more SNPs. These genes may therefore appear more significant due to the increased number of tests performed. Hence, we corrected for multiple testing as follows. For a given candidate gene on the "B" list, if p min is the minimum p-value found in the pooled genotyping of stage I of the GWAS for all the SNPs genotyped in the gene, and N is the number of SNPs tested, then we computed the corrected minimum p-value p corr using the formula 
Since roughly 50% of the SNPs in any chromosomal region are in high linkage disequilibrium (LD) (36), we used (N+1)/2 as the exponent. The Category "B" genes were then ranked by these corrected minimum p-values and SNPs were selected from the top of the ranked list until our resources were exhausted.
SNP Selection
We chose all SNPs within exons, regardless of allele frequency, and all SNPs within +/-2kb of annotated gene promoters where the European American minor allele frequency was at least 4%. We then chose tag SNPs for all European American LD bins (37) crossing the exons of the candidate genes, with 2 SNPs for each bin with 3 or more SNPs. SNPs meeting these criteria were chosen first from those selected for individual genotyping in the companion pooled study (Bierut et al., manuscript in preparation), and then to cover the physical regions as uniformly as possible if there was choice available for the other SNPs. In addition, we included specific SNPs which have been reported in the literature as being associated with nicotine dependence (8, 9, 18, 34) .
Pooled Genotyping
See Bierut et al. (manuscript in preparation, submitted to Human Molecular Genetics simultaneously with this manuscript) for a description of the pooled genotyping.
Individual Genotyping
For individual genotyping, we designed custom high-density oligonucleotide arrays to interrogate SNPs selected from candidate genes, as well quality control SNPs. Each SNP was interrogated by twenty-four 25mer oligonucleotide probes synthesized on a glass substrate. The twenty-four features comprise 4 sets of 6 features interrogating the neighborhoods of SNP reference and alternate alleles on forward and reference strands. Each allele and strand is represented by five offsets: -2, -1, 0, 1, and 2 indicating the position of the SNP within the 25-mer, with zero being at the thirteenth base. At offset 0 a quartet was tiled, which includes the perfect match to reference and alternate SNP alleles and the two remaining nucleotides as mismatch probes. When possible, the mismatch features were selected as purine nucleotide substitution for purine perfect match nucleotide and a pyrimidine nucleotide substitution for a pyrimidine perfect match nucleotide. Thus, each strand and allele tiling consisted of 6 features comprising five perfect match probes and one mismatch.
Individual Genotype Cleaning
Individual genotypes were cleaned using a supervised prediction algorithm for the genotyping quality, compiled from 15 input metrics that describe the quality of the SNP and the genotype. The genotyping quality metric correlates with a probability of having a discordant call between the Perlegen platform and outside genotyping platforms (i.e. non-Perlegen HapMap project genotypes). A system of 10 bootstrap aggregated regression trees was trained using an independent data set of concordance data between Perlegen genotypes and HapMap project genotypes. The trained predictor was then used to predict the genotyping quality for each of the genotypes in this data set (see the supplement for more information regarding cleaning).
Population Stratification Analysis
In order to avoid false positives due to population stratification, we performed an analysis using the STRUCTURE software (38). This program identifies subpopulations of individuals who are genetically similar through a Markov chain Monte Carlo sampling procedure using markers selected across the genome. Genotype data for 289 high performance SNPs were analyzed across all 1,929 samples. This analysis revealed no evidence for population admixture.
Genetic Association Analysis
An ANOVA analysis testing the predictive power of various phenotypes indicated that gender and site (U.S.A. or Australian) were the most informative, and that age and other demographic variables did not account for significant additional trait variance ( 
where α is the intercept, g is gender coded 0 or 1 for males or females, respectively, and s is site coded as 0 or 1 for U.S.A. or Australian, respectively. The variable G represents genotype and is coded as the number of copies of the risk allele, defined as the allele more common in cases than in controls. It follows from equation (2) that the risk due to genotype is being modeled using a log-linear (i.e., multiplicative) scale rather than an additive scale. Maximum likelihood estimates for the coefficients and confidence intervals for odds ratios were computed using the SAS software package (39).
The predictors of our base model were gender and site. We then tested whether the addition of genotype and gender by genotype interaction to the base model significantly increased the predictive power, and used the resulting 2 degree of freedom chi-squared statistic to rank the SNPs by the corresponding p-values. Table 8A shows the formulas for the odds ratios in terms of the coefficients.
Following these primary analyses, we further analyzed the top ranked SNPs for significant evidence of dominant or recessive modes of inheritance. This was done using a logistic regression of the form
where H is 1 for heterozygotes and 0 otherwise. When H is significant the interpretation is that the genetic effect deviates significantly from the log-linear model. We then compute odds ratios for dominant and recessive models as described in Table 8B .
Linkage Disequilibrium
We estimated r 2 correlation separately in cases and controls for all pairs of SNPs within 1
Mb windows using an EM algorithm as implemented in the computer program Haploview 
Correcting for Multiple Testing
To account for multiple testing we estimated the False Discovery Rate (FDR) (23, 24) to control the proportion of false positives among our reported signals. Since Category "A" genes were considered to have a higher prior probability of association, we followed the where w was defined so that the average of the weights is 1 (this depends on the number of SNPs selected for "A" and "B" genes). For every weighted p-value p w0 we computed a q-value q w0 that has the property that the FDR is no greater than q w0 among all SNPs with q w < q w0 (24, 43) . This was done using the computer program QVALUE (version 1.1, http://faculty.washington.edu/jstorey/qvalue) (44). Our estimates of the FDR are based on the qvalues.
This method of estimating the FDR does not take into account LD. Therefore, as an additional measure to correct for multiple testing and assess statistical significance, we estimated the FDR using permutations and p-values weighted for "A" and "B" genes, which preserves the LD structure. This was done by performing 1,000 random permutations of the case-control status and testing the permuted data for association. The significance of a p-value from the original data was assessed by counting the number of times a more significant weighted p-value occurs in the random permutations, where the weights were the same as those used for the FDR estimates. CHRNA5-CHRNA3-CHRNB4 clusters of nicotinic receptor genes . 
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